World Cancer Diagnostics and Therapeutics

CME Accredited

Sep 13-14, 2019

London, United Kingdom

World Cancer Diagnostics and Therapeutics


Welcome to the official site of "World Cancer Diagnostics and Therapeutics" to be held during September 13-14, 2019 at London, UK, concentrating on the topic "Lightning talks on Novel Advancements to terminate Cancer".

The aim of the Conference is to provide a platform to the Researchers and Practitioners from both Academia as well as Industry to meet the share cutting-edge development in the field of World Cancer.

This get-together will offer you exceptional prospects to coordinate with Academic and Clinical oncology Specialists, Clinical oncology Researchers, Medical Research Departments, Faculty of Health Sciences, C-level official, Faculty of Healthcare, Deans, Professors and PhD Students from Medical Universities. It is a worldwide stage to examine and find out about Fostering and Latest Innovations in Cancer Diagnosis.

Also this is your best opportunity to share your thoughts, best practice activities, or to discuss your research related to the current issues and meet the Specialists in this fields. Early identification builds the achievement rate of treatment regimens. Hence this gathering will concentrate on the successful treatment answers for checking the regularity level of the disease along with its application for the individuals well-being.

United Kingdom government tries to manufacture a world class well -being framework to enhance the nature of medicinal services for its population. Looking at the improvement of disease instruction programs in Britain from the perspective of the historical backdrop of wellbeing training it is obvious that the Clinical researchers approach towards the growth control of the diseases has imparted some highlights in accordance to the general individuals concern.

According to the report by Grand View Research, Inc., the overall development diagnostics advertisement is depended upon to achieve USD 232.7 billion by 2025. Steady introduction of innovative things combined with the requirement for early conclusion of the illness is the prime factor driving the market development.

[ Note: The first round of abstract submission will start from October 15, 2018. ]

Details of World Cancer Diagnostics and Therapeutics:

Conference Name



World Cancer Diagnostics and Therapeutics


September 13-14, 2019

Kenji Suzuki
Associate Professor
University of Illinois


Kenji Suzuki joined Department of Electric and Computer Engineering and Medical Imaging Research Center, Illinois Institute of Technology, as Associate Professor in 2014. Before that, he worked in Research and Development Center, Hitachi Medical Corporati

Researches :

  • His research interests include computational intelligence and machine learning in medical imaging, computer-aided detection and diagnosis, and medical image processing and analysis. He published more than 300 papers (including 110 peer-reviewed journal papers). His papers were cited more than 8,000 times by other researchers, and he has an h-index of 39. He is one of top 10 most cited researchers in the world in the computer-aided diagnosis field by Google Scholar. He is inventor on 30 patents (including 12 granted patents), which were licensed to several companies and commercialized. He published 10 books and 22 book chapters, and edited 12 journal special issues. He was awarded more than 25 grants as the P.I. including NIH R01 and ACS grants.
Andrey Sorokin
Medicine Nephrology and Microbiology Immunology
Medical College of Wisconsin, USA

Researches :

  • My research is primarily focused on characterizing the molecular mechanisms underlying the activation and termination of signaling pathways, as well as defining the cellular consequences of specific stimulation of these cascades in systems relevant for the signaling from G-protein coupled receptors. In renal mesangium endothelin-1 (ET-1) exerts excessive contraction, proliferation and extracellular matrix accumulation leading to glomerulosclerosis and kidney failure. We are studying ET-1 –induced signaling cascades underlying proliferation-associated and oxidative stress related renal glomerular diseases. We also investigate the posttranslational regulation of Cyclooxygenase-2 (COX-2), the key inducible enzyme in the production of prostaglandins. Our lab has demonstrated the anti-apoptotic effect of COX-2 in a number of cell systems and provided evidence that COX-2 promotes cell survival by a mechanism linking increased expression of pro-survival genes coupled to inhibition of NO- and superoxide-mediated apop
Nir Peled
Pulmonary Institute , Rabin Medical Center

Program Overview